{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:06:49Z","timestamp":1761581209548},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1097\/dad.0000000000000027","type":"journal-article","created":{"date-parts":[[2014,6,21]],"date-time":"2014-06-21T13:05:52Z","timestamp":1403355952000},"page":"e125-e128","source":"Crossref","is-referenced-by-count":5,"title":["Secondary Diffuse Large B-cell Lymphoma After Chemotherapy for Acute Myeloid Leukemia"],"prefix":"10.1097","volume":"36","author":[{"given":"Marnie R.","family":"Ririe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott R.","family":"Florell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney R.","family":"Miles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith L.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-16-20210202","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/CCO.0b013e32834bcc2a","article-title":"Therapy-related myeloid neoplasms.","volume":"23","author":"Leone","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"R2-16-20210202","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012.","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"R3-16-20210202","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10552-007-9097-2","article-title":"Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002.","volume":"19","author":"Yamamoto","year":"2008","journal-title":"Cancer Causes Control"},{"key":"R4-16-20210202","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":". Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"R5-16-20210202","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":". Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.","volume":"105","author":"Smith","year":"2011","journal-title":"Br J Cancer"},{"key":"R6-16-20210202","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":". Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"key":"R7-16-20210202","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":". Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"R8-16-20210202","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-3148.2011.01078.x","article-title":". Haemolysis after treatment with intravenous immunoglobulin due to anti-A.","volume":"21","author":"Morgan","year":"2011","journal-title":"Transfus Med"},{"key":"R9-16-20210202","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":". Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"R10-16-20210202","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":". The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"R11-16-20210202","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJM199012203232510","article-title":"Cancers complicating organ transplantation.","volume":"323","author":"Penn","year":"1990","journal-title":"N Engl J Med"},{"key":"R12-16-20210202","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.sder.2006.12.002","article-title":"Complications and adverse reactions in the use of newer biologic agents.","volume":"26","author":"Callen","year":"2007","journal-title":"Semin Cutan Med Surg"},{"key":"R13-16-20210202","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00000478-200205000-00009","article-title":". Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms.","volume":"26","author":"Abruzzo","year":"2002","journal-title":"Am J Surg Pathol"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000000027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:56:55Z","timestamp":1620950215000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000372-201407000-00016"}},"subtitle":["Looking for the Unexpected Diagnosis"],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000000027","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}